001007669 001__ 1007669
001007669 005__ 20231027114405.0
001007669 0247_ $$2doi$$a10.1016/j.seizure.2023.03.020
001007669 0247_ $$2ISSN$$a1059-1311
001007669 0247_ $$2ISSN$$a1532-2688
001007669 0247_ $$2Handle$$a2128/34461
001007669 0247_ $$2pmid$$a37004393
001007669 0247_ $$2WOS$$aWOS:001031705300001
001007669 037__ $$aFZJ-2023-02152
001007669 082__ $$a610
001007669 1001_ $$0P:(DE-HGF)0$$aKohle, Felix$$b0$$eCorresponding author
001007669 245__ $$aStatus epilepticus and benzodiazepine treatment: Use, underdosing and outcome - insights from a retrospective, multicentre registry
001007669 260__ $$aOxford [u.a.]$$bElsevier$$c2023
001007669 3367_ $$2DRIVER$$aarticle
001007669 3367_ $$2DataCite$$aOutput Types/Journal article
001007669 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1685006542_28121
001007669 3367_ $$2BibTeX$$aARTICLE
001007669 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001007669 3367_ $$00$$2EndNote$$aJournal Article
001007669 520__ $$aObjective: To explore the reasons for and outcomes of non- or undertreatment with benzodiazepines (BZDs) in status epilepticus (SE).Methods: We retrospectively analysed all SE patients from the urban area of Cologne over two years.Results: 328 SE patients were eligible, and only 72% were initially treated with BZDs. Of these, only 21.6% were treated sufficiently with BZDs according to current guidelines. SE patients not initially treated with BZDs were significantly older, had less often known epilepsy, had a prolonged arrival time to the emergency room, and presented more often with a non-generalised convulsive semiology. Regarding adequate dosages, patients with a generalised convulsive SE seemed to benefit from a sufficient BZD dosing with significantly shortened mean ventilation duration (37.1 to 208 h), decreased mean intensive care unit (1.7 to 5 days) and in-hospital stay (4.1 to 8.8 days). In contrary, aggressive BZD treatment in non-generalised convulsive SE resulted in a longer inpatient stay (9.2 to 5.8 days) and lower favourable outcome rates at discharge (16% to 63%).Conclusions: The current SE treatment guidelines for first-line BZD therapy in SE were violated in most patients. Sufficient BZD dosing was beneficial in generalised convulsive SE, but not in other forms of SE. SE semiology might be crucial for treatment decisions with BZDs. Further treatment evidence especially in non-generalised convulsive SE is urgently needed.Keywords: Anticonvulsants; Benzodiazepines; Critical care; Guideline adherence; Seizures.
001007669 536__ $$0G:(DE-HGF)POF4-5251$$a5251 - Multilevel Brain Organization and Variability (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001007669 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001007669 7001_ $$0P:(DE-HGF)0$$aMadlener, Marie$$b1
001007669 7001_ $$0P:(DE-HGF)0$$aBruno, Emanuel F.$$b2
001007669 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon R.$$b3$$ufzj
001007669 7001_ $$0P:(DE-HGF)0$$aLimmroth, Volker$$b4
001007669 7001_ $$0P:(DE-HGF)0$$aBurghaus, Lothar$$b5
001007669 7001_ $$0P:(DE-HGF)0$$aMalter, Michael P.$$b6
001007669 773__ $$0PERI:(DE-600)2002585-3$$a10.1016/j.seizure.2023.03.020$$gVol. 107, p. 114 - 120$$p114 - 120$$tSeizure$$v107$$x1059-1311$$y2023
001007669 8564_ $$uhttps://juser.fz-juelich.de/record/1007669/files/Kohle_2023_European%20Journal%20of%20Epilepsy_Status%20epilepticus%20and%20benzodiazepine%20treatment.pdf$$yRestricted
001007669 8564_ $$uhttps://juser.fz-juelich.de/record/1007669/files/Post%20print.pdf$$yOpenAccess
001007669 909CO $$ooai:juser.fz-juelich.de:1007669$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
001007669 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b3$$kFZJ
001007669 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5251$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001007669 9141_ $$y2023
001007669 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-29
001007669 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-29
001007669 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001007669 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-22$$wger
001007669 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-22
001007669 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-22
001007669 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-22
001007669 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-22
001007669 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSEIZURE-EUR J EPILEP : 2022$$d2023-10-22
001007669 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-22
001007669 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-22
001007669 920__ $$lyes
001007669 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
001007669 980__ $$ajournal
001007669 980__ $$aVDB
001007669 980__ $$aUNRESTRICTED
001007669 980__ $$aI:(DE-Juel1)INM-3-20090406
001007669 9801_ $$aFullTexts